HealthcareServices

Cancer Cachexia Market Research: Growth Projections and Trends 2030

February 20, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer cachexia market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Cancer Cachexia Market be in 2030 compared with 2026?

The cancer cachexia market has experienced robust growth in recent times. This market is projected to expand from $2.6 billion in 2025 to $2.75 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. Historically, this expansion can be ascribed to a rising occurrence of late-stage cancer diagnoses, enhanced clinical understanding of cachexia management, an expanding distribution network through hospital pharmacies, the initial uptake of anabolic agents, and a broader provision of supportive oncology care.

The cancer cachexia market size is projected to experience substantial growth in the coming years, with its value expected to reach $3.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. This expansion during the forecast period is fueled by an escalating demand for personalized cachexia treatments, increased clinical research into innovative mechanisms, the broadening of outpatient oncology services, the expanding application of digital patient monitoring tools, and a heightened emphasis on quality-of-life outcomes. Prominent trends anticipated in the forecast period include the increasing utilization of combination drug regimens, a growing focus on muscle preservation therapies, the rising adoption of nutritional supplementation strategies, the proliferation of anti-inflammatory cachexia treatments, and more advanced monitoring of cachexia progression.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

What Drivers Are Guiding Growth Patterns In The Cancer Cachexia Market?

The rising incidence of cancer is projected to fuel the growth of the cancer cachexia market in the coming period. Cancer is a medical condition where abnormal cells multiply without control in the body, forming tumors and interfering with typical bodily processes. Various elements contribute to the increasing instances of cancer, such as shifts in lifestyle, environmental factors, an aging demographic, genetic susceptibilities, improvements in diagnostic methods leading to quicker identification, and enhanced awareness encouraging more people to seek medical attention. Breakthroughs in medical technology and a more comprehensive understanding of cancer and its complexities are leading to more frequent diagnoses and reporting of cancer cachexia. Healthcare practitioners are improving their capability to identify cachexia symptoms, which supports earlier interventions and the commencement of treatment. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, it was estimated that 165,000 Australians were newly diagnosed with cancer in 2023, which is more than 450 cases daily, and males made up about 55% of these diagnoses. Hence, the growing prevalence of cancer is serving as a primary driver for the expansion of the cancer cachexia market.

How Is The Cancer Cachexia Market Divided Into Segments?

The cancer cachexia market covered in this report is segmented –

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate

2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs

What Industry Trends Are Transforming The Cancer Cachexia Market?

Prominent companies operating within the cancer cachexia market are innovating medications, such as monoclonal antibodies for cachexia, to create targeted treatments for cancer cachexia, aspiring to enhance body weight, muscle mass, and the overall quality of life for those afflicted. A monoclonal antibody specifically for cachexia operates by targeting and inhibiting the factors that lead to muscle and weight loss. For example, in September 2024, Pfizer Inc., a pharmaceutical company based in the US, reported positive findings from its Phase 2 study of Ponsegromab, a monoclonal antibody designed to target GDF-15, in individuals with cancer cachexia. The study illustrated a notable increase in body weight and enhancements in muscle mass, appetite, and physical activity, with the 400 mg dose demonstrating the most compelling outcomes. Building on these encouraging discoveries, Pfizer intends to launch registration-enabling studies in 2025 to further examine Ponsegromab’s capability for treating cancer cachexia.

Which Leading Companies Dominate The Cancer Cachexia Market Share?

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

How Does The Cancer Cachexia Market Perform Across Major Global Regions?

North America was the largest region in the cancer cachexia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer Cachexia Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Browse Through More Reports Similar to the Global Cancer Cachexia Market 2026, By The Business Research Company

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Chemotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795